STOCK TITAN
  1. Home
  2. News
  3. NSTG

NanoString Technologies, Inc. - NSTG STOCK NEWS

Welcome to our dedicated page for NanoString Technologies news (Ticker: NSTG), a resource for investors and traders seeking the latest updates and insights on NanoString Technologies stock.

NanoString Technologies, Inc. (NASDAQ: NSTG) is a renowned provider of life science tools for translational research and molecular diagnostics. Established in 2008, NanoString's technology is pivotal in enabling a diverse array of basic research, translational medicine, and in vitro diagnostics applications. The company's flagship product, the nCounter® Analysis System, is celebrated for its ability to profile the expression of hundreds of genes, miRNAs, or copy number variations simultaneously with high sensitivity and precision. This system has been referenced in over 300 peer-reviewed publications, underscoring its widespread adoption and scientific credibility.

The nCounter® system's versatility extends to diagnostic use as the nCounter Dx Analysis System, further solidifying NanoString's footprint in the molecular diagnostics landscape. The technology stands out for its cost-effectiveness and efficiency, making it a valuable tool for applications such as biomarker discovery and validation, as well as other translational research endeavors.

Among recent developments, NanoString Technologies has been embroiled in significant litigation with 10x Genomics, Inc. Notably, the European Unified Patent Court (UPC) declined to issue a second preliminary injunction against NanoString, allowing the company to continue its operations in specific jurisdictions. However, injunctions from the Regional Court Munich I and the UPC still impose restrictions on the sale and service of NanoString's CosMx Spatial Molecular Imager (SMI) instruments and reagents for RNA detection in Europe.

The legal battles extend to the United States, where 10x Genomics has filed multiple suits against NanoString alleging patent infringement related to the GeoMx Digital Spatial Profiler and the CosMx SMI. Recently, a jury in the U.S. District Court for the District of Delaware awarded 10x Genomics over $31 million in damages, asserting that NanoString's GeoMx products willfully infringed on several patents.

Despite these legal challenges, NanoString continues to thrive as a leader in its field, providing essential tools that drive significant discoveries in oncology, immunology, neuroscience, and beyond. The company's commitment to advancing human health through molecular diagnostics and translational research tools remains unwavering.

News

NanoString Announces Completion of Financing to Support Restructuring Process

Rhea-AI Summary
NanoString Technologies, Inc. secures $47.5 million in new financing, supporting its mission to serve life sciences researchers worldwide. The funding will aid the company through its restructuring process and support key business activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
97.93%
Tags
none
-
News

NanoString Takes Steps to Restructure Its Business and Protect Its Mission to Map the Universe of Biology

Rhea-AI Summary
NanoString Technologies, Inc. (NSTG) is initiating voluntary Chapter 11 restructuring proceedings to protect its business and explore strategic alternatives, including potential sale of the company. This comes after unfavorable outcomes in patent litigation with competitor 10x Genomics, Inc. The company has secured $40 million in financing to facilitate the process and continue serving life sciences researchers worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-78.02%
Tags
none
-
News

NanoString Launches the CosMx 6,000 plex RNA Assay and Showcases Whole Transcriptome Imaging Capability

Rhea-AI Summary
NanoString Technologies, Inc. (NSTG) announced the availability of the CosMx Human 6K Discovery Panel, the first single-cell spatial panel measuring over 6,000 RNA targets. The company will present groundbreaking whole transcriptome imaging capabilities at the AGBT General Meeting. Independent researchers will showcase studies powered by the whole transcriptome panel, highlighting its potential to advance research in areas such as Alzheimer's Disease and colorectal cancer. NanoString will also feature its spatial solutions in ten AGBT-accepted abstracts, demonstrating the innovative technology's potential to revolutionize precision medicine and diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.58%
Tags
none
News

NanoString’s CosMx SMI Achieves Whole Transcriptome Imaging at Single-Cell Resolution

Rhea-AI Summary
NanoString Technologies, a leading life science tools provider (NASDAQ: NSTG), marked a major milestone by releasing the first public dataset of the CosMx Whole Transcriptome Panel, showcasing true single-cell resolution imaging. The company achieved a scientific moonshot by visualizing the expression of almost 19,000 genes in situ, enabling researchers to explore millions of cells per experiment, identify rare cell types, and understand cell-to-cell interactions in spatial context. This transformative technology will be commercially launched in 2025, offering nearly 40x the coverage of competing platforms at a lower cost per single cell and higher cellular throughput. NanoString also plans to launch the CosMx Human 6K Discovery Panel in Q1 2024, empowering researchers to delve deeper into cell states and function, explore intricate cell-to-cell interactions, and deliver new insights into spatial cellular responses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

NanoString Reports Inducement Grants Under Nasdaq Listing Rules

Rhea-AI Summary
NanoString Technologies, Inc. (Nasdaq: NSTG) announced equity inducement awards to 10 new employees, granting 34,925 restricted stock units as material inducements. One-third of the RSUs vest on the first market trading day on or following the first anniversary of the grant date and one-third annually each year on the first market trading day on or after the second and third anniversaries of the grant date, subject to continued service. The awards were made outside of NanoString’s current equity plan, the 2022 Equity Incentive Plan, and under NanoString’s 2018 Inducement Equity Incentive Plan and related award agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.72%
Tags
none
-
News

NanoString to Webcast Presentation from 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
NanoString Technologies, Inc. (NSTG) to present at the 42nd annual J.P. Morgan healthcare conference. Brad Gray, president and CEO, to present on January 10, 2024, at 5:15pm ET. Webcast available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
conferences
News

NanoString Comments on Delaware District Court Verdict

Rhea-AI Summary
NanoString Technologies, Inc. (NASDAQ: NSTG) commented on the November 17th verdict of a jury in the U.S. District Court for the District of Delaware, finding that NanoString GeoMx® Digital Spatial Profiler products infringe patents licensed to 10x Genomics and awarding approximately $31 million in damages. NanoString plans to seek to have the verdict overturned or amended in post-trial motions and expects to appeal to the U.S. Court of Appeals for the Federal Circuit, specializing in patent disputes. The company remains resolute in its belief that the asserted patents are invalid, that they don’t infringe these patents, and that they should be vindicated on appeal. The verdict does not prevent NanoString from continuing to sell GeoMx products worldwide, and the company is dedicated to enabling scientists to map the universe of biology and saving patients’ lives. NanoString also announced the withdrawal of its full year 2023 and fourth quarter financial guidance, pending a review of the impact of this litigation outcome on its business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-50%
Tags
none
-
News

10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies

Rhea-AI Summary
10x Genomics (TXG) Wins Patent Infringement Case Against NanoString, Awarded Over $31 Million in Damages: A jury in the U.S. District Court for the District of Delaware unanimously ruled in favor of 10x Genomics in the patent infringement suit against NanoString, awarding over $31 million in damages for willful infringement of seven patents. The ruling is the third against NanoString in six months, confirming serial infringement of 10x patents. Post-trial, 10x intends to seek ongoing royalties, treble damages, attorney's fees, a permanent injunction, and pre- and post-judgment interest. 10x's Chief Legal Officer emphasized the importance of protecting patents and thanked the jury for recognizing 10x's innovation. The ruling is based on extensive evidence, including testimony from key figures. This case is part of a larger legal battle, with another suit pending against NanoString in the U.S. District Court for the District of Delaware.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-50%
Tags
none
-
News

NanoString Technologies to Present Portfolio of Cutting-edge Brain Research and Novel Spatial Biology Applications for Neuroscience

Rhea-AI Summary
NanoString Technologies (NSTG) to Present Groundbreaking Brain Research at Neuroscience 2023 in Seattle, Including New CosMx™ Mouse Universal Cell Characterization RNA Panel. The company will showcase its digital spatial profiling and spatial imaging platforms, with 22 posters and two symposia at the Society for Neuroscience annual meeting. The presentation will offer insights into single cell signaling for healthy and diseased brain tissue, with potential future patient benefits. The company also secured 22 other poster presentations on various neuro-related topics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.36%
Tags
conferences
News

NanoString to Webcast Presentations from Upcoming Healthcare Conferences

Rhea-AI Summary
NanoString Technologies, Inc. (NASDAQ:NSTG) to Present at Stifel 2023 Healthcare Conference and Jefferies London Healthcare Conference. Tom Bailey and Doug Farrell to participate in fireside discussion and corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.36%
Tags
conferences

FAQ

What is the market cap of NanoString Technologies (NSTG)?

The market cap of NanoString Technologies (NSTG) is approximately 5.1M.

What is NanoString Technologies' primary business?

NanoString Technologies provides life science tools for translational research and molecular diagnostics, including the nCounter® Analysis System.

What is the nCounter® Analysis System?

The nCounter® Analysis System is a technology that profiles the expression of hundreds of genes, miRNAs, or copy number variations simultaneously with high sensitivity and precision.

What are some applications of NanoString's technology?

NanoString's technology is used in basic research, translational medicine, biomarker discovery, and validation, among other applications.

Has NanoString been involved in any legal issues recently?

Yes, NanoString has been involved in litigation with 10x Genomics concerning patent infringements related to its GeoMx and CosMx products.

What was the outcome of the recent lawsuit in the U.S. District Court for the District of Delaware?

A jury awarded 10x Genomics over $31 million in damages, finding that NanoString's GeoMx products willfully infringed on several patents.

What is the significance of the nCounter Dx Analysis System?

The nCounter Dx Analysis System is an extension of the nCounter® technology for diagnostic use, making it crucial for molecular diagnostics applications.

How many peer-reviewed publications have cited the nCounter® system?

The nCounter® system has been cited in more than 300 peer-reviewed publications.

What is the cost advantage of NanoString's technology?

NanoString's technology offers a cost-effective way to profile gene expressions and other molecular data with high accuracy and sensitivity.

What are the legal implications of the injunctions against NanoString in Europe?

The injunctions prevent NanoString from selling or providing services using its CosMx SMI instruments and reagents for RNA detection in several European countries.

How does NanoString contribute to advancements in human health?

NanoString provides essential tools for molecular diagnostics and translational research, driving significant discoveries in areas like oncology, immunology, and neuroscience.

Stock NSTG logo
NanoString Technologies, Inc.

Nasdaq:NSTG

NSTG Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

NSTG Stock Data

5.07M
39.41M
3.17%
106.45%
12.55%
Medical Instruments & Supplies
Healthcare
Link
United States
Seattle